drugset / Trial / NCT06025773
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
RandomizedCrossoverOpen-labelTreatment
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
Timeline
- Start
- 2023-09-15
- Primary completion
- 2024-04-19
- Completion
- 2024-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcium carbonate | Other / unclassified | 600 mg | Oral |
| Subject | Lansoprazole | Other / unclassified | 15 mg | Oral |